CureVac
A biopharmaceutical company developing prophylactic and therapeutic application of messenger RNA, which can be used to develop vaccines. It was founded in 2000 and is located in Tübingen, Germany.
9
Funding Rounds
$1.8b
Money raised
Overview
A biopharmaceutical company developing prophylactic and therapeutic application of messenger RNA, which can be used to develop vaccines. It was founded in 2000 and is located in Tübingen, Germany.
| Name | Phone | Social networks | |
|---|---|---|---|
| In**** Ho*** | - | - | linkedin twitter |
| Fl***** vo* de* M�**** | - | - |
| Name | Phone | Social networks | |
|---|---|---|---|
| In**** Ho*** | - | - | linkedin twitter |
Funding
Funding series
Funding Series Analysis
The company CureVac has raised a total of $1.15b in funding over 9 rounds.
Key Insights:
- CureVac Venture round, February 2, 2021: $450m
- CureVac Grant (money), September 15, 2020: $306m
- CureVac Series F round, November 3, 2015: $119.63m
- CureVac Series F round, November 2015: $29.5m
- CureVac Series E round, March 5, 2015: $76m
- CureVac Series D round: $104.43m
- CureVac funding round, May 10, 2010: $35.25m
- CureVac Series B round: $26.68m
- CureVac Private Funding round, July 21, 2020: $640m
CureVac Venture round, February 2, 2021
$450m
CureVac Grant (money), September 15, 2020
$306m
CureVac Series F round, November 3, 2015
$119.63m
CureVac Series F round, November 2015
$29.5m
CureVac Series E round, March 5, 2015
$76m
CureVac Series D round
$104.43m
CureVac funding round, May 10, 2010
$35.25m
CureVac Series B round
$26.68m
CureVac Private Funding round, July 21, 2020
$640m
Industries
CureVac is active in the following industries:
- Vaccine
- Pharmaceutical industry
- Therapeutics
- Research and development
- Drug discovery
- Biomedical engineering
- Biopharmaceutical
- Cancer
- Oncology
- Engineering
- Technology
- Biology
- Biotechnology
- RNA-based and RNA-targeted therapeutics
- Healthcare
- Internal medicine
- Medicine